Inter-alpha inhibitor protein (IaIp) is an endogenous serine protease inhibitor in human plasma. Circulating IaIp levels were lower in 51 patients with severe sepsis than in healthy volunteers. Mean levels were 688 The inter-alpha inhibitor protein (IaIp) family is a group of plasma-associated serine protease inhibitors. Members of this family are composed of heavy and light polypeptide subunits that are covalently linked by a glycosaminoglycan [1] . The light chain, also called bikunin, is responsible for the serine protease inhibitory activity of the molecules. The name "bikunin" reflects the presence of 2 protease-inhibiting domains of the Kunitz type [2] .
Inter-alpha inhibitor protein (IaIp) is an endogenous serine protease inhibitor in human plasma. Circulating IaIp levels were lower in 51 patients with severe sepsis than in healthy volunteers. Mean levels were 688 746 ‫ע‬ 290 n p 18 P p .0102 with 28-day mortality rates and Acute Physiology and Chronic Health Evaluation II scores and directly correlated with antithrombin III, protein C, and protein S levels. The administration of IaIp (30 mg/kg body weight intravenously) increased the 50% lethal dose in mice by 100-fold after an intravenous challenge of Escherichia coli. Thus, human IaIp may be a useful predictive marker and potential therapeutic agent in sepsis.
The inter-alpha inhibitor protein (IaIp) family is a group of plasma-associated serine protease inhibitors. Members of this family are composed of heavy and light polypeptide subunits that are covalently linked by a glycosaminoglycan [1] . The light chain, also called bikunin, is responsible for the serine protease inhibitory activity of the molecules. The name "bikunin" reflects the presence of 2 protease-inhibiting domains of the Kunitz type [2] .
In normal plasma, bikunin is found mostly in a complex form as inter-alpha inhibitor (IaI), which has a molecular weight of 225 kDa, and pre-alpha inhibitor (PaI), which has molecular weight of 120 kDa [3, 4] . In IaI, bikunin is linked to 2 heavy polypeptide chains, H1 and H2, whereas, in PaI, only a single heavy chain (H3) is linked to bikunin [3] . In these complexed forms, bikunin remains inactive until its release by partial proteolytic degradation, a mechanism that serves as a means to regulate activity [5] . After cleavage from the complex, the activated bikunin is cleared rapidly from plasma by glomerular filtration, a process that is facilitated by its low molecular weight and by receptormediated uptake [6] . A growing collection of experimental and clinical data have indicated that members of the IaIp family are involved in many physiological and pathological activities, such as tumor invasion, metastasis [7] , and stabilization of the extracellular matrix [8, 9] . Recently, the involvement of IaIp in inflammatory diseases has become an area of intensive investigation.
Sepsis and septic shock are associated with the activation of the innate immunity [10] , complement [11] , and coagulation systems and the accompanying inhibition of the fibrinolytic system [12] . It is characterized clinically by systemic inflammation, coagulopathy, hypotension, and multiple organ dysfunction. A network of specific proteinases activates clotting, fibrinolytic, and complement factors during severe sepsis. Proteases from endotoxin-activated polymorphonuclear leukocytes can trigger tissue and organ damage [13] and enhance the nonspecific proteolysis of plasma clotting and complement factors [14] .
The release of neutrophil proteinases, especially human leukocyte elastase, has been implicated in the pro-gress of complications in patients with sepsis [15] . Plasma IaIp is particularly sensitive to cleavage by neutrophil elastase, and the light chain released from the IaIp complex exerts its inhibitory activity on serine proteases [16] . In vitro, IaIp has been shown to inhibit several serine proteases that are involved in inflammation, such as elastase, plasmin, and cathepsin G [17] . The results of clinical studies of patients with severe sepsis have revealed significant systemic IaIp consumption, together with an extended secretion of elastase [18] [19] [20] .
In the present article, we describe a quantitative competitive immunoassay for the measurement of IaIp (both IaI and PaI) in plasma using a monoclonal antibody (MAb) specific against human bikunin. This assay was used to measure the levels of IaIp in 51 septic plasma samples. We also evaluated the potential of the assay to predict the clinical outcome in sepsis, the correlation between IaIp levels and the coagulation parameters antithrombin III, protein S, and protein C, and the potential beneficial effect of IaIp administration in an experimental mouse model of sepsis.
PATIENTS, MATERIALS, AND METHODS

Patient selection and sample collection.
Plasma samples were collected from 51 patients with sepsis who had been randomized to the placebo group of a large, phase 3 multicenter sepsis trial of an interleukin-1 receptor antagonist [21] . Samples were obtained at study entry within 24 h of the onset of severe sepsis. Patients were classified into severe sepsis and/or septic shock groups according to the consensus definitions established at the American College of Chest Physicians/Society of Critical Care Medicine Consensus conference [22] . A clinical evaluation committee reviewed the clinical and laboratory findings in each patient enrolled in the clinical trial. The committee then applied a consistent prespecified and standardized classification system to define the source of infection, organ dysfunction, and probable causative organism(s) for sepsis in each patient. The APACHE II score was also determined for each patient [23] . We used plasma samples from 25 healthy volunteers who had no acute illness as controls.
Plasma was obtained from endotoxin-free heparinized blood samples (Chromogenix). Blood samples were placed on ice and then centrifuged at 4ЊC for 15 min at 1500 g within 30 min. Tubes were then frozen at Ϫ70ЊC and shipped on dry ice to the research laboratory.
Preparation of human IaIp. Human plasma-derived IaIp was isolated from an industrial-scale clotting factor VIII (FVIII) concentrate (Octapharma Pharmaceuticals), which was found to contain a relatively large amount of IaIp. IaIp was successfully separated from FVIII/von Willebrand factor by sizeexclusion high-performance liquid chromatography (BioSec; Merck). IaIp that contained fractions concentrated by diafiltration were freeze-dried in the presence of saline for long-term storage. The purity of IaIp was estimated to be ∼70%, as determined by SDS-PAGE and a competitive ELISA that used IaIp purified by immunoaffinity chromatography on immobilized MAb 69.31 as a standard. The major contaminants in this IaIp preparation were FVIII and von Willebrand factor.
Generation of MAbs against IaIp.
A panel of MAbs against human IaIp was generated by the subtractive immunization protocol described by Williams et al. [31] . BALB/c mice were tolerized by intraperitoneal (ip) injection of 100 mg of an IaIp-containing solvent/detergent-treated plasma fraction (Octapharma Pharmaceuticals). This was followed by ip injections of cyclophosphamide (Cytoxan; Bristol-Myers Squibb) at a dose of 100 mg/kg body weight 15 min, 24 h, and 48 h after tolerogen exposure. Tolerized mice then were immunized 3 times on days 18, 33, and 48 by ip injection of 100 mg of an IaIpcontaining solvent/detergent-treated human plasma fraction that had also undergone pasteurization. Three days after the third immunization, spleen cells were harvested and fused with PAI myeloma cells, as described by Lane et al. [32] . After fusion, hybridoma cells were hypoxanthine-aminopterin-thymidine selected and cloned simultaneously in a methylcellulose-based formulation (ClonaCell-HY; Stem Cell Technologies). Individual clones were expanded in 96-well plates, and antibody-secreting hybridomas were screened for reactivity against human IaIp in an ELISA or Western blot assay. The positive clone selected for the present study was designated as MAb 69. 31 .
Determination of IaIp levels by competitive ELISA. A competitive ELISA that used murine MAb 69.31 was used to measure IaIp levels. Then, 96-well Immunolon-4 plates (Dynex) were coated with purified IaIp (300 ng) in 50 mmol/L carbonate buffer (pH 9.6) and incubated overnight at 4ЊC. A serial dilution of purified IaIp in PBS that contained 1% rat serum was used to establish a standard curve. For the quantitative analysis of IaIp levels in plasma, 50 mL of plasma samples diluted 1:25 in PBS or serially diluted IaIp were added to individual wells of a 96-well plate. After the addititon of 50 mL of MAb 69.31 to each well, plates were incubated for 1 h at 37ЊC and subsequently washed using an automated plate washer (Labsystem). The bound MAb 69.31 was detected by adding horseradish peroxidase-conjugated goat anti-mouse IgG (human absorbed) (Biosource) for 1 h at 37ЊC. After washing, 100 mL of 1-Step ABTS (Pierce) was added to the wells, and the absorbance at 405 nm was measured on ELISA plate reader (BioTek). Each plasma sample was tested in triplicate, and assays were done and repeated 3 times independently.
Determination of antithrombin III (AT-III), protein C, and protein S levels. Citrated plasma was obtained and stored at Ϫ70ЊC until it was analyzed. AT-III activity was measured by colorimetric methods (Diagnostica Stago). Plasma was incubated with heparin and thrombin in excess. Thrombin was measured according to its amidolytic activity on the chromogenic substrate. Values between 80% and 120% were considered to be normal. Protein C activity and free protein S were measured by a coagulation-based assay (Compact coagulation analyzer; Asnieres).
Experimental animals and animal model. Six-week-old female, specific pathogen-free BALB/c mice (Charles River Laboratories) were used for the mortality study. National Guidelines for Animal Care and Use in Biomedical Research were followed. A standard LD 50 model with intravenous (iv) injection of both the bacteria and IaIp or saline controls that had been approved by the Institutional Animal Care and Use Committee was used for the studies. Escherichia coli O18:K1:H7 (strain Bort, a gift from Dr. A. Cross, University of Maryland, Baltimore) was administered intravenously via tail-vein injection under light CO 2 anesthesia, followed in 45-60 min by an iv injection of saline or IaIp at 30 mg/kg body weight. E. coli O18:K1:H7 is a highly virulent, serum-resistant isolate with a LD 50 of 2-100 cfu/mouse, depending on the assay used [33, 34] . The results of preliminary in vitro testing demonstrated that IaIp had no direct inhibitory effects on the growth of this strain of E. coli even at concentrations 11000 mg/mL.
Bacteria were grown in culture to the midlog phase in TSB media (BBL) and then were washed in PBS and diluted in PBS to concentrations of 10 2 -10 6 by spectrophotometer measurement. The bacterial concentration was confirmed by direct colony counts of serial 10-fold dilutions of PBS on MacConkey plates (BBL). The mortality rate was monitored for 48 h, and the LD 50 of the challenge strain of E. coli was calculated according to the method of Reed and Muench [24] .
Statistical methods. Statistical analyses were done using the Statistica software package (version 5.0; Statsoft). The nonparametric Mann-Whitney U test was used for comparisons between the treatment and control groups. Correlation analysis between different variables was done with the Spearman rank correlation test.
was considered to be significant. P ! .05 Decreased plasma inter-alpha inhibitor protein (IaIp) levels in patients with severe sepsis. The IaIp levels differed significantly between the healthy control subjects and patients with severe sepsis (survivors and nonsurvivors, ) and between the survivor and non-P p .0001 survivor groups ( ). The whisker plots show a range between P p .0103 maximum and minimum measured values, and the box extends from the 25th to the 75th percentile, with a line at the median.
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subjects were mg/L ( ) (figure 3). Statistical 872 ‫ע‬ 234
n p 25 analyses indicated that the differences in the IaIp plasma levels between the healthy controls and patients with severe sepsis and between the survivor and nonsurvivor groups with severe sepsis were highly significant ( and , re-P p .0001 P p .0103 spectively). Significant differences were also found between the IaIp levels in patients with septic shock (65% of patients) and those without ( ) (figure 4). 290 n p 18 P p .0102 To determine whether there was a correlation between plasma IaIp levels and mortality, patients were divided into the following 4 groups, according to the size of the decrease in plasma IaIp levels: group 1, plasma levels !300 mg/L; group 2, plasma levels between 300 and 600 mg/L; group 3, plasma levels between 600 and 900 mg/L; and group 4, normal plasma levels 1900 mg/L. The results revealed that 3 (60%) of 5 patients in group 1, 12 (52%) of 23 in group 2, and 3 (21%) of 14 in group 3 died during the 28-day study. In contrast, only 1 (11%) of 9 patients in group 4, who had normal IaIp levels (933 mg/ L), died during the same time period (figure 5). The results suggest that plasma IaIp levels are inversely correlated with the mortality rate in patients with severe sepsis.
Plasma levels of IaIp correlate with severity of illness in sepsis. To determine whether there was a correlation between plasma IaIp levels and disease severity and/or risk of mortality, patients with sepsis who had been admitted to the intensive care unit were scored using APACHE II, a helpful tool in the prognosis and prediction of the mortality in sepsis. All data were collected within the first 24 h of admission, and the most aberrant values were used for scoring. As shown in figure 6A, there was a statistically significant ( ) negative corre-P p .016 lation between APACHE II scores and IaIp levels in the plasma of 26 patients with severe sepsis (Spearman correlation coefficient, ). r p Ϫ0.47 Decreases in plasma IaIp levels in sepsis correlate with consumption of coagulation regulators. Levels of AT-III, protein C, and protein S in plasma from 26 patients with severe sepsis were measured and evaluated by the Spearman correlation test, to determine whether there was a correlation between changes in the plasma levels of these proteins and the plasma levels of IaIp. The results showed that, in patients with severe sepsis, the decrease of IaIp levels was positively correlated with the decrease in the plasma levels of AT-III ( ; r p 0.58 ), protein C ( ; ), and protein S P p .0021 r p 0.403 P p .042 ( ; ) (figure 6B-6D). r p 0.45 P p .021
In vivo IaIp administration improves survival after E. coli injection. To determine whether the administration of IaIp during sepsis would reduce mortality, a lethality study in mice was done. Mice were inoculated intravenously with E. coli O18: K1 (strain Bort) at 5 different doses (10 cfu/mouse in groups of 10 mice for each dosage level). One hour after bacterial challenge, mice were injected intraperitoneally with IaIp at a dose of 30 mg/kg body weight (8 mice from each group) or with an equivalent volume of saline (2 mice from each group). Lethality was measured as the number of animals that died because of the infectious challenge over the next 48 h. Additionally, IaIp was administered at a dose of 30 mg/kg body weight in another group of 10 untreated animals, as a control group, to ensure that the IaIp caused no direct toxicity itself.
All animals in this control group remained healthy throughout the 48-h study period after the IaIp injection.
For mice treated with saline after inoculation with E. coli, the LD 50 was log 10 1.61. In contrast, the LD 50 in the IaIp-treated animals was log 10 3.69 ( ), a difference that indicates that P ! .001 a 100-fold higher doses of E. coli was required for lethality in the IaIp-treated animals. These results indicate that a preparation containing human IaIp provides significant benefit in protecting mice from an otherwise lethal challenge with a gramnegative bacteria.
DISCUSSION
Bikunin, the light chain of IaIp, has been shown to inhibit a large number of serine proteases, including factor Xa and kallikrein, 2 proteases that are involved in the coagulation pathway. The finding that bikunin inhibits cell-surface plasmin [5] and lipopolysaccharide-induced stimulation of neutrophils [25] indicates that this protein is also a part of the regulatory system that controls acute inflammation.
The physiological role of bikunin is still unknown, but the fact that no persons with a complete absence of bikunin have been ever been reported [5] suggests that bikunin is essential for life. In the present article, the 2 bikunin-containing molecules found in plasma, IaI and PaI, (referred to together as IaIp) were both recognized in Western blot and immunoprecipitation assays by MAb 69.31. We also determined that the epitope defined by MAb 69.31 is located in bikunin. In addition, we demonstrated that MAb 69.31 effectively blocks the trypsin inhibitory activity of bikunin, which suggests that the epitope defined by this MAb is located in the active site of the molecule (authors' unpublished data).
Using MAb 69.31, we developed a competitive ELISA that can accurately measure the total levels of IaIp (IaI and PaI) in body fluids. This is in contrast to previously described sandwich-type ELISA assays that used 2 different polyclonal antibodies against heavy chains (H1 and H2), and thus could only measure IaI [26] , or that relied on polyclonal anti-H3 and antibikunin antibodies that could only detect PaI [27] .
We evaluated samples from 51 patients with severe sepsis with our competitive ELISA. Our results demonstrated a significant decrease in plasma IaIp levels (a 20%-90% reduction), compared with plasma levels in healthy individuals. Statistically significant differences were found between the mean plasma IaIp levels of healthy controls, between survivor and nonsurvivor groups of patients with sepsis, and between septic patients with and without shock. Furthermore, the decrease of IaIp levels correlated with the clinical outcome. Although Balduyck et al. [19] also reported that IaI levels were significantly decreased in plasma samples collected on admission from patients with sepsis, their assay only detected IaI and did not predict the clinical outcome of the patients. Taken together, these results suggest that the measurement of total bikunin-containing molecules in the plasma might have greater predictive value in sepsis than measurement of either IaI or PaI alone.
Although total plasma levels of IaIp decrease during sepsis, serum levels of PaI actually increase in patients with inflammatory disease, a finding that is consistent with the resemblance of PaI expression to "positive" hepatic acute-phase proteins. However, the increased synthesis of PaI is counterbalanced by its enhanced catabolism of PaI during inflammatory disease [20, 27] . This is in contrast to IaI, which rapidly decreases during inflammation and sepsis and has been described as a "negative" acute-phase protein. The mechanism responsible for the regulation of both components of IaIp remains to be determined.
It is likely that the increased levels of PaI in early inflammatory states are followed by significant reduction during severe sepsis, when hepatocellular dysfunction causes the inadequate synthesis of many proteins [28] . Systemic proteolysis during sepsis induces degradation of IaIp [29] and leads to the rapid appearance of breakdown products in the urine. It has been reported that PaI is more susceptible than IaI to proteolysis by stimulated neutrophils [27] . Thus, decreased biosynthesis, in combination with increased proteolysis, appears to be responsible, at least in part, for the reduction in plasma IaIp in patients with severe sepsis [20] .
Serial measurements in patients with sepsis have consistently demonstrated a prolonged procoagulant state manifested by AT-III and protein C deficiency [30] . In contrast to the results reported by Balduyck et al. [19] , a positive correlation between IaIp levels and AT-III, protein C, and protein S was found in our study. These findings support the fact that plasma serine protease inhibitors such as IaIp and AT-III are consumed during sepsis. A relationship between the IaIp levels and the clinical severity of the disease, as indicated in the APACHE II score, was also demonstrated by our results. In addition, we found that the mortality rate for patients with severely decreased levels of IaIp was significantly higher than that of patients with more moderate reductions. These findings suggest that plasma IaIp levels may be a useful predictor of mortality in sepsis. It is crucial to identify these high-risk patients, so that aggressive therapy can be initiated early, before the disease progresses. The prognostic value of IaIp levels might be significantly improved by serial measurements of IaIp levels during disease progression. Current studies are investigating this possibility during the full course of sepsis in a cohort of critically ill patients with a wide spectrum of illness.
Although the physiological importance of IaIp remains elusive, the fact that the relatively high concentrations of IaIp found in normal plasma rapidly diminish during sepsis offers a therapeutic rationale for the replacement of this endogenous serine protease inhibitor during sepsis. The results of current studies with IaIp administration in a murine model of gramnegative bacteremia support the therapeutic value of IaIp replacement for the treatment of septic shock. This method of therapy is also supported by a recent publication by Yang et al. [35] , which showed improved hemodynamics and a significant survival advantage after the administration of IaIp in a rat cecal ligation and puncture model for polymicrobial peritonitis. These findings, together with the results presented here, provide a strong justification for further experimental and clinical investigation into the therapeutic utility of IaIp and suggest that restoring the balance between plasma proteases and inhibitors may provide an effective strategy for reducing the severe complications of sepsis in humans.
